Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Cash & Equivalents (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Cash & Equivalents for 12 consecutive years, with $118.6 million as the latest value for Q1 2026.

  • For Q1 2026, Cash & Equivalents fell 34.25% year-over-year to $118.6 million; the TTM value through Mar 2026 reached $118.6 million, down 34.25%, while the annual FY2025 figure was $125.1 million, 41.14% down from the prior year.
  • Cash & Equivalents hit $118.6 million in Q1 2026 for Cartesian Therapeutics, down from $125.1 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $219.2 million in Q3 2024 and bottomed at $76.9 million in Q4 2023.
  • Average Cash & Equivalents over 5 years is $130.3 million, with a median of $118.6 million recorded in 2026.
  • Year-over-year, Cash & Equivalents skyrocketed 176.44% in 2024 and then plummeted 41.14% in 2025.
  • Cartesian Therapeutics' Cash & Equivalents stood at $106.4 million in 2022, then fell by 27.74% to $76.9 million in 2023, then surged by 176.44% to $212.6 million in 2024, then crashed by 41.14% to $125.1 million in 2025, then decreased by 5.19% to $118.6 million in 2026.
  • According to Business Quant data, Cash & Equivalents over the past three periods came in at $118.6 million, $125.1 million, and $143.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.